MedTrace Logo

Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism (AIRE)

NCT04003116 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2022-08-18

No results posted yet for this study

Summary

The primary objective is to evaluate the efficacy of the treatment with supplementary oxygen added to conventional anticoagulant treatment in patients with Intermediate-risk pulmonary embolism.

The secondary objective is to evaluate the safety of the treatment with supplementary oxygen added to conventional anticoagulant treatment in patients with Intermediate-risk pulmonary embolism.

Conditions

Interventions

DRUG

Oxygen gas

Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.

Sponsors & Collaborators

  • Sociedad Española de Neumología y Cirugía Torácica

    collaborator OTHER

  • Ministry of Health, Spain

    lead OTHER_GOV

Principal Investigators

  • David Jiménez · IRYCIS, Alcala de Henares University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-11
Primary Completion
2022-04-24
Completion
2022-07-25

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04003116 on ClinicalTrials.gov